FDA approves a liquid form of Kamada's AATD drug Glassia

07/5/2010 | Reuters

The FDA approved a liquid version of Glassia, Kamada's intravenous drug for alpha-1 antitrypsin deficiency, a condition that can lead to lung-tissue damage and emphysema. Kamada said it is looking for a partner to develop the treatment for other indications.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC
Sr Product Manager Global Marketing (US/DA/00/0085/SL) - 14000009V3
Abbott
Chicago, IL
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Vice President, Information Technology
HealthPartners
MN